Cargando…

Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis

The use of immunobiological agents for the treatment of autoimmune diseases is increasing in medical practice. Anti-TNF therapies have been increasingly used in refractory autoimmune diseases, especially rheumatoid arthritis, with promising results. However, the use of such therapies has been associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dias, Olívia Meira, Pereira, Daniel Antunes Silva, Baldi, Bruno Guedes, Costa, André Nathan, Athanazio, Rodrigo Abensur, Kairalla, Ronaldo Adib, Carvalho, Carlos Roberto Ribeiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075924/ https://www.ncbi.nlm.nih.gov/pubmed/24626274 http://dx.doi.org/10.1590/S1806-37132014000100012

Ejemplares similares

Lung-dominant connective tissue disease among patients with interstitial lung disease: prevalence, functional stability, and common extrathoracic features
por: Pereira, Daniel Antunes Silva, et al.
Publicado: (2015)

Idiopathic pulmonary fibrosis can be a transient diagnosis
por: de Oliveira, Martina Rodrigues, et al.
Publicado: (2016)

Eosinophilic pneumonia: remember topical drugs as a potential etiology
por: Dias, Olívia Meira, et al.
Publicado: (2018)

Pulmonary involvement in rheumatoid arthritis: evaluation by radiography and spirometry
por: Kawassaki, Alexandre Melo, et al.
Publicado: (2015)

Desaturation – distance ratio: a new concept for a functional assessment of interstitial lung diseases
por: Pimenta, Suzana Pinheiro, et al.
Publicado: (2010)

Tomographic pleuropulmonary manifestations in rheumatoid arthritis: a pictorial essay
por: Bridi, Guilherme das Posses, et al.
Publicado: (2023)

Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response ,
por: Pimenta, Suzana Pinheiro, et al.
Publicado: (2013)

Lung cysts in chronic paracoccidioidomycosis
por: Costa, André Nathan, et al.
Publicado: (2013)

Usual interstitial pneumonia: a pattern or a disease? A reflection upon the topic
por: Kawano-Dourado, Leticia, et al.
Publicado: (2013)

PET/CT and interstitial lung disease
por: Sawamura, Marcio Valente Yamada, et al.
Publicado: (2022)

Combined pulmonary fibrosis and emphysema: an increasingly recognized condition
por: Dias, Olívia Meira, et al.
Publicado: (2014)

Characterization and outcomes of pulmonary alveolar proteinosis in Brazil: a case series
por: de Athayde, Rodolfo Augusto Bacelar, et al.
Publicado: (2018)

Birt-Hogg-Dubé syndrome: metalloproteinase activity and response to doxycycline
por: Pimenta, Suzana Pinheiro, et al.
Publicado: (2012)

Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations
por: Freitas, Carolina Salim Gonçalves, et al.
Publicado: (2015)

COVID-19 and pulmonary alveolar proteinosis: an unusual combination
por: Colares, Philippe de Figueiredo Braga, et al.
Publicado: (2022)

Bronchiectasis: moving from an orphan disease to an unpleasant socioeconomic burden
por: Athanazio, Rodrigo Abensur
Publicado: (2021)

Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
por: Gissel, C., et al.
Publicado: (2016)

Long-term treatment of rheumatoid arthritis with adalimumab
por: Murdaca, Giuseppe, et al.
Publicado: (2013)

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
por: Capsoni, Franco, et al.
Publicado: (2005)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Sweet’s Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet’s Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
por: Paul, Prodip, et al.
Publicado: (2021)

Diffuse cystic lung diseases: differential diagnosis
por: Baldi, Bruno Guedes, et al.
Publicado: (2017)

Right lung exclusion in massive pulmonary thromboembolism
por: Athanazio, Rodrigo Abensur, et al.
Publicado: (2015)

Association between pulmonary artery to aorta diameter ratio with pulmonary hypertension and outcomes in diffuse cystic lung diseases
por: Baldi, Bruno Guedes, et al.
Publicado: (2021)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2016)

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis
por: Nguyen, Dao X., et al.
Publicado: (2018)

Immunohistological features related to functional impairment in lymphangioleiomyomatosis
por: Nascimento, Ellen Caroline Toledo do, et al.
Publicado: (2018)

Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2017)

Interpretation of autoantibody positivity in interstitial lung disease and lung-dominant connective tissue disease
por: Pereira, Daniel Antunes Silva, et al.
Publicado: (2013)

Successful Treatment of Pseudoseptic Arthritis Contained Massive Purulent Fluid with Adalimumab in Rheumatoid Arthritis
por: Chung, Chong Hyuk, et al.
Publicado: (2020)

Epipericardial fat necrosis: increasing the rate of diagnosis by disseminating knowledge within a single institution
por: Giassi, Karina de Souza, et al.
Publicado: (2018)

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
por: Chara, Luis, et al.
Publicado: (2012)

Digital Vasculitis in a Patient with Rheumatoid Arthritis Responded Well to Adalimumab
por: Kobak, Senol, et al.
Publicado: (2014)

Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014)

Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
por: Gissel, C., et al.
Publicado: (2017)

Beyond the joints in rheumatoid arthritis: Effects of adalimumab on hematologic and lipid indices
por: Sakthiswary, R., et al.
Publicado: (2012)

Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia
por: Deakin, Claire T., et al.
Publicado: (2023)

Adalimumab induced interstitial lung disease
por: Aqsa, Anum, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_au4tjmc7a935pcr2ukvoh7anj8